밀로퍼옥시다아제 검사: 혈관 위험 및 그 한계

카테고리
조항
Vascular Health 검사 해석 2026년 업데이트 환자 친화적

MPO reflects immune-cell oxidative activity that can accompany vascular injury, but it is a context marker—not a diagnosis. Here is how clinicians place it beside lipids, blood pressure, glucose, kidney function, and symptoms.

📖 약 11분 📅
📝 게시됨: 🩺 의학적 검토: ✅ 근거 기반
⚡ 간단한 요약 v1.0 —
  1. What MPO measures: Myeloperoxidase is an enzyme released mainly by activated neutrophils and monocytes that can generate hypochlorous acid during immune activation.
  2. Assay-dependent range: A commonly used EDTA-plasma MPO assay classifies values below 350 pmol/L as lower risk, but laboratories use different methods and cutoffs.
  3. Not a heart-disease diagnosis: A high MPO result cannot show whether coronary arteries are narrowed, whether plaque is present, or whether chest pain is cardiac.
  4. MPO cardiac risk: MPO adds limited prognostic information in selected people, especially acute chest-pain cohorts, but does not replace LDL-C, ApoB, blood pressure, HbA1c, or smoking history.
  5. Troponin comes first: New chest pressure, breathlessness, sweating, fainting, or pain spreading to the jaw or arm requires urgent clinical assessment and ECG/troponin testing—not an MPO blood test.
  6. 맥락 지표: Non-HDL cholesterol, ApoB, lipoprotein(a), hs-CRP, eGFR, urine ACR, glucose, and blood pressure provide more actionable risk context.
  7. Common false context: Recent infection, autoimmune activity, smoking, kidney dysfunction, strenuous exercise, and acute tissue injury may raise myeloperoxidase levels.
  8. 실질적인 다음 단계: Repeat an unexpected MPO result only when well and use the same laboratory and specimen type; do not start supplements or medication solely to lower MPO.

What an MPO Blood Test Actually Measures

A myeloperoxidase test measures an oxidative enzyme released by activated white cells; it reflects immune activity that can contribute to oxidation within vessel walls. It cannot diagnose coronary artery disease, predict an individual heart attack with certainty, or explain chest pain on its own. As of September 12, 2026, I use MPO only as a secondary clue beside established cardiovascular risk data.

Myeloperoxidase test shown as an enzyme interaction near a detailed artery cross-section
그림 1: Activated immune enzyme activity is shown beside an arterial wall cross-section.

Myeloperoxidase (MPO) is stored in neutrophils and monocytes and helps those cells make hypochlorous acid, a potent antimicrobial oxidant. In a vessel wall, the same chemistry can modify LDL particles, reduce nitric-oxide availability, and make plaque biology less stable; that is why MPO drew attention as a vascular-inflammation marker.

An MPO result is not interchangeable with a cholesterol result. A person may have LDL-C of 92 mg/dL and a temporarily high MPO after a respiratory illness, while another person with MPO in a lower range may still have high lifetime risk because ApoB is 145 mg/dL, blood pressure is 154/94 mmHg, and they smoke.

Kantesti AI는 AI 혈액검사 분석기 that reads specialized vascular markers alongside the standard results that change decisions most often, rather than treating one enzyme as a verdict. In my clinical work, the most useful question is rarely “Is MPO high?”; it is “What potentially modifiable risk is present with it?” Explore the wider 바이오마커 참조 가이드 for the tests commonly found on a cardiovascular panel.

Dr. Thomas Klein has seen patients become understandably alarmed by an MPO flag despite normal ECGs and reassuring symptom assessments. That anxiety is avoidable when the report states plainly that MPO describes a biological pathway, whereas imaging, symptoms, troponin, and conventional risk factors determine whether heart disease is likely.

The enzyme is not the antibody

MPO enzyme testing for vascular risk is different from an MPO-ANCA antibody test used in suspected vasculitis. One measures circulating enzyme concentration or activity; the other looks for an immune antibody and has an entirely different clinical purpose.

Why MPO Is Linked to Oxidative Stress in Arteries

MPO links to vascular risk because it can oxidize lipoproteins and impair nitric-oxide signalling within an inflamed arterial wall. The mechanism is biologically plausible, but plausibility does not make MPO a treatment target or a screening diagnosis.

Oxidative myeloperoxidase activity illustrated around LDL particles in an artery wall
그림 2: MPO-related oxidation is depicted where immune cells meet retained lipoproteins.

MPO uses hydrogen peroxide and chloride to generate hypochlorous acid, often abbreviated HOCl. HOCl can chlorinate tyrosine residues on proteins and alter HDL and LDL function; these chemical footprints are measurable in research tissue studies, although a routine plasma value cannot locate where the oxidation occurred.

Atherosclerosis is not simply “rust in the arteries.” It involves ApoB-containing particles entering and being retained in the artery wall, local immune recruitment, endothelial dysfunction, and sometimes plaque rupture; an oxidized LDL result may be conceptually related but carries its own assay limitations.

The 2003 chest-pain study by Brennan et al. found that higher MPO identified greater near-term event risk even when initial troponin was negative (Brennan et al., 2003). That result was clinically interesting because MPO may rise before detectable myocardial cell injury, not because it proved that an infarction was underway.

One nuance often missed online: circulating MPO can originate from activated immune cells outside coronary arteries. Gum disease, an acute viral illness, inflammatory arthritis, chronic kidney disease, and tobacco exposure all provide alternative explanations, so the test has poor anatomical specificity.

When Clinicians May Consider Ordering MPO

Clinicians may consider an MPO blood test when conventional cardiovascular risk appears incomplete or when a specialist is refining risk in a patient with several borderline findings. Routine population screening is not supported by major prevention guidelines.

Cardiovascular risk laboratory review with MPO sample preparation and lipid reports
그림 3: Specialized MPO testing is interpreted only after standard cardiovascular risk measures.

The test is sometimes ordered in preventive cardiology for a person with premature family history, metabolic risk, borderline traditional scores, or unexplained progression of vascular disease. It is less helpful in a 24-year-old with no symptoms, normal blood pressure, LDL-C of 68 mg/dL, and no major risk exposures because the pre-test likelihood of actionable disease is very low.

The evidence is honestly mixed on whether MPO materially improves decisions once modern risk assessment is complete. The 2019 ACC/AHA prevention guideline emphasizes pooled risk estimation, blood pressure, diabetes, smoking, cholesterol, coronary artery calcium in selected adults, and risk-enhancing factors such as Lp(a), rather than MPO as a routine test (Arnett et al., 2019).

많은 환자에서, hs-CRP is more familiar, but it answers a different question: it is a liver-derived acute-phase protein rather than a neutrophil enzyme. Read how symptoms and timing complicate high hs-CRP interpretation before assuming either marker identifies a diseased artery.

I usually reserve discussion of MPO for a follow-up visit, not a rushed annual check-up. A result that cannot alter LDL lowering, blood-pressure treatment, smoking cessation, diabetes care, or imaging decisions may add noise rather than useful precision.

MPO Cardiac Risk Testing Is Not an MPO-ANCA Test

An MPO cardiac-risk assay and an MPO-ANCA test are different laboratory investigations with different units, methods, and clinical consequences. A raised vascular MPO does not mean vasculitis, and a positive MPO-ANCA does not quantify cardiovascular oxidative stress.

Separate laboratory assay materials illustrate MPO enzyme testing and MPO antibody testing
그림 4: Enzyme concentration and antibody detection are separate laboratory questions.

MPO-ANCA detects antibodies directed against myeloperoxidase and is used with symptoms, urine findings, kidney function, imaging, and specialist assessment when small-vessel vasculitis is suspected. Coughing blood, rapidly worsening kidney function, purpura, neuropathy, or inflammatory eye disease warrant prompt medical evaluation; a cardiovascular MPO panel is not the appropriate work-up.

By contrast, MPO cardiac assays commonly report pmol/L, ng/mL, or assay-specific activity. ANCA laboratories often report antibody index units or U/mL with their own positivity threshold, which means a number from one report cannot be converted safely into a number from the other.

칸테스티는 AI 검사 결과 해석 서비스는 designed to separate similarly named tests by specimen, method, unit, and clinical question. This distinction matters particularly when patients upload several reports over years; see our guide to ANCA patterns and MPO for antibody-specific follow-up.

A laboratory flag is not a diagnosis. If an MPO-ANCA is positive, the estimated probability of vasculitis depends heavily on compatible symptoms and objective organ findings, while a lone low-positive result can occur in other autoimmune conditions, infections, and some medication exposures.

Why MPO Cannot Rule In or Rule Out a Heart Attack

MPO cannot rule in or rule out myocardial infarction because it does not measure heart-muscle injury and rises in many non-cardiac inflammatory states. Acute chest symptoms require an ECG, serial high-sensitivity troponin testing, vital signs, and clinician assessment.

Emergency cardiac assessment showing ECG tracing equipment beside serial troponin samples
그림 5: Acute chest symptoms require ECG and troponin pathways rather than MPO alone.

High-sensitivity troponin reflects myocardial injury, though even troponin needs interpretation because kidney disease, tachyarrhythmia, myocarditis, and severe hypertension can elevate it. A changing value over 1 to 3 hours, symptoms, ECG findings, and local assay thresholds are more informative than a single MPO result.

In Brennan et al.’s 2003 New England Journal of Medicine cohort, MPO added prognostic information among patients presenting with chest pain, including some with initially negative troponin (Brennan et al., 2003). That does not justify using MPO at home or in primary care to exclude an emergency; the study population was already receiving urgent hospital assessment.

New pressure or tightness lasting more than 10 minutes, pain with exertion, fainting, severe shortness of breath, cold sweating, or pain spreading to the jaw, back, or arm should prompt emergency services. Our practical 흉통 혈액 검사 가이드 explains why timing changes every cardiac marker.

A normal MPO is not a permission slip to ignore symptoms. Conversely, an elevated MPO without symptoms is usually a risk-discussion issue, not an emergency department diagnosis.

LDL and Non-HDL Cholesterol Provide Essential Context

LDL-C and non-HDL cholesterol provide essential context for MPO because atherosclerosis requires exposure to ApoB-containing lipoproteins, not oxidative stress alone. An elevated MPO with persistently low atherogenic cholesterol generally carries a different implication from the same MPO value with LDL-C of 190 mg/dL.

Arterial cross-section shows retained LDL particles and immune enzyme activity together
그림 6: Atherogenic lipoprotein burden gives MPO-related oxidation its clinical context.

LDL-C 수치가 190 mg/dL 이상이면 is considered severe hypercholesterolaemia in major guidelines and typically calls for active clinical treatment regardless of a calculated 10-year score. Non-HDL cholesterol equals total cholesterol minus HDL-C and captures LDL plus triglyceride-rich remnants; it is particularly useful when triglycerides exceed 175 mg/dL.

MPO may help describe a hostile vascular environment, but LDL and non-HDL show the particle cargo that can be retained in arterial tissue. In a patient with LDL-C 178 mg/dL and MPO 610 pmol/L on a validated assay, I would focus first on familial risk, ApoB, treatment options, adherence, and sometimes coronary artery calcium—not supplements marketed as antioxidants.

Kantesti AI highlights the pattern between lipid results and inflammatory context, including a high LDL that causes no symptoms. The absence of chest pain does not make LDL exposure harmless, and a high MPO does not identify which lipid intervention is right for an individual.

Statins lower LDL-C and reduce cardiovascular events, but a fall in MPO is not a validated treatment goal. Measurements should serve decisions that improve outcomes, not become a scoreboard for biochemical optimisation.

ApoB Often Explains Risk Better Than MPO Alone

ApoB often adds more actionable cardiovascular information than MPO because each atherogenic particle carries one ApoB molecule. A high ApoB identifies a high number of particles capable of entering artery walls, even when LDL-C looks only modestly raised.

ApoB-containing lipoprotein particles compared with MPO enzyme molecules near an artery
그림 7: Particle number and inflammatory enzyme activity answer different vascular-risk questions.

ApoB is especially useful when triglycerides are high, insulin resistance is present, or LDL-C and non-HDL-C disagree. For example, LDL-C of 106 mg/dL with triglycerides of 260 mg/dL and ApoB of 125 mg/dL may indicate more atherogenic particles than LDL-C alone suggests.

The ACC/AHA guideline lists ApoB of 130 mg/dL 이상이면 as a risk-enhancing factor, particularly when triglycerides are persistently 200 mg/dL or more (Arnett et al., 2019). There is no comparable guideline threshold at which MPO alone mandates a statin, CT scan, or angiogram.

이런 영역에서는 숫자보다 맥락이 더 중요합니다. ApoB to ApoA1 ratio explainer shows why an apparently acceptable LDL value can conceal particle-related risk.

When I review a panel, an ApoB value that is consistently high across two fasting or non-fasting draws usually changes the conversation more than a one-off MPO result. The reason is simple: we have much stronger outcome-trial evidence for lowering atherogenic particle burden.

Lipoprotein(a) and Family History Change the Meaning of MPO

Lipoprotein(a), or Lp(a), and premature family history can elevate lifetime cardiovascular risk independently of MPO. A single Lp(a) measurement is usually reasonable in adulthood because levels are largely inherited and remain relatively stable.

Lipoprotein(a) particle visualization beside a family cardiovascular history review
그림 8: Inherited Lp(a) exposure and family history can outweigh a single MPO result.

Many guidelines consider Lp(a) at 50 mg/dL 또는 125 nmol/L 이상 a risk-enhancing level, although mg/dL and nmol/L cannot be converted precisely because particle size varies. A parent, sibling, or child with myocardial infarction before age 55 in men or 65 in women is another signal that deserves formal review.

In the 2007 EPIC-Norfolk analysis, Meuwese and colleagues found higher MPO associated with future coronary disease among apparently healthy adults (Meuwese et al., 2007). That association does not tell us whether inherited Lp(a), lifelong ApoB exposure, hypertension, or smoking is the dominant risk driver for a particular person.

Patients sometimes assume a “normal cholesterol” report rules out inherited risk. It does not; our Lp(a) screening guide explains why Lp(a) can be clinically relevant even when LDL-C is 90 mg/dL.

MPO may modestly refine a discussion in a specialist setting, but it should not distract from documenting relatives’ ages at events, checking Lp(a), and investigating possible familial hypercholesterolaemia when LDL-C is very high.

Blood Pressure and Smoking Can Outweigh an MPO Result

Blood pressure and smoking status frequently influence cardiovascular risk more than MPO because both have proven causal links to heart attack, stroke, kidney disease, and premature death. A single office blood pressure of 140/90 mmHg needs confirmation, but persistent elevation deserves action regardless of MPO.

Home blood pressure monitor beside a vascular health laboratory sample and smoking cessation tools
그림 9: Blood pressure and tobacco exposure are established, modifiable vascular-risk drivers.

The usual diagnostic threshold for hypertension is office blood pressure of 임신 중 혈압이 in many settings, while home or ambulatory averages of 135/85 mmHg 이상이면 are commonly considered elevated. Guidelines vary by country and patient risk, but repeated properly measured readings matter far more than one anxious clinic measurement.

Smoking activates neutrophils, damages endothelium, and can elevate inflammatory markers, which makes an MPO result particularly difficult to interpret in a current smoker. Stopping tobacco lowers cardiovascular risk substantially even if a biomarker does not normalize immediately; no “detox” product substitutes for cessation support.

Kantesti can organize a cardiovascular report alongside results from a secondary-hypertension laboratory work-up, but an app cannot diagnose hypertension from a single reading. A validated home cuff, seated rest for 5 minutes, and a 7-day log are often more useful next steps.

I have seen a 47-year-old patient fixate on an MPO of 560 pmol/L while overlooking average home readings near 151/96 mmHg. Treating the established pressure problem was the priority; MPO did not alter that hierarchy.

Glucose, Kidney Function and Metabolic Risk Complete the Picture

Glucose status and kidney function are necessary context for MPO because diabetes and chronic kidney disease accelerate vascular risk through several pathways at once. HbA1c of 6.5% or higher can diagnose diabetes when confirmed appropriately, while eGFR below 60 mL/min/1.73 m² for 3 months indicates chronic kidney disease.

Metabolic risk panel with glucose, HbA1c, kidney filtration and MPO laboratory concepts
그림 10: Glucose control and kidney filtration influence both vascular risk and MPO interpretation.

Diabetes increases atherosclerotic risk through glycation, altered lipoprotein metabolism, endothelial dysfunction, and renal injury. HbA1c of 5.7%~6.4% indicates prediabetes, but anemia, recent transfusion, haemoglobin variants, and kidney disease can make HbA1c misleading; fructosamine testing is occasionally useful when that occurs.

Kidney disease can raise MPO because reduced clearance and chronic immune activation may coexist, while it independently raises cardiovascular risk. eGFR should be interpreted with urine albumin-creatinine ratio: an ACR of 30 mg/g 이상 is abnormal albuminuria and can change prevention priorities even with an eGFR above 60.

Metabolic syndrome is defined by a cluster of waist, triglycerides, HDL-C, blood pressure, and glucose abnormalities, not by MPO. Review the five measurable metabolic-syndrome criteria rather than relying on a vague “oxidative stress” label.

The practical issue is compounding risk. MPO of 500 pmol/L means more in a person with HbA1c 7.8%, ACR 120 mg/g, triglycerides 240 mg/dL, and hypertension than in a lean, normotensive person recovering from a cold.

Non-Cardiac Reasons Myeloperoxidase Levels Rise

Myeloperoxidase levels can rise with infection, autoimmune activity, smoking, chronic kidney disease, periodontal inflammation, acute tissue stress, and recent strenuous exercise. These causes make a single elevated MPO result nonspecific for coronary disease.

Neutrophil enzyme response shown with exercise, immune activity and kidney function contexts
그림 11: Several non-cardiac states can activate MPO-releasing white cells.

A febrile illness can change white-cell activation over days, whereas hs-CRP often peaks and falls on a different timetable. If a test was drawn during fever, after dental treatment, or within a few days of a severe workout, I would not use that MPO value to make a long-term cardiovascular judgment.

Intense endurance exercise can transiently change neutrophil counts, creatine kinase, CRP, and oxidative markers. A 52-year-old marathon runner with AST 89 IU/L after a race may also have a noisy inflammatory panel; the safer choice is recovery and repeat testing, as discussed in our 운동 관련 크레아틴 가이드.

Systemic autoimmune disease and vasculitis require their own clinical assessment rather than being reduced to an MPO cardiac score. Persistently high ESR or CRP plus rash, joint swelling, weight loss, nerve symptoms, abnormal urine, or fevers merits clinician review; ESR causes are broad.

A mildly elevated MPO after a cold is usually not an emergency. It is a reason to check whether the sample was timed sensibly and whether the conventional risk profile has been assessed.

MPO Reference Ranges Depend on the Assay and Specimen

MPO reference ranges depend on the laboratory method, calibration, and whether the sample is EDTA plasma or serum. A commonly cited EDTA-plasma classification uses below 350 pmol/L as lower risk and 540 pmol/L or higher as high, but these are not universal diagnostic boundaries.

MPO immunoassay analyzer processes EDTA plasma samples with quality control materials
그림 12: Assay method and specimen type determine how an MPO result can be compared.

Some reports use ng/mL, while others use pmol/L, and a conversion is not safe without knowing the assay calibrator and molecular form measured. Pre-analytical handling matters too: delayed processing, sample type, storage temperature, and cellular activation after collection can change measured concentrations.

The categories below are best viewed as one assay-family example, not as a universal normal range. A result of 420 pmol/L may be called intermediate on one EDTA-plasma report, but the same clinical sample may not have a directly comparable serum result from another laboratory.

Kantesti AI는 AI 바이오마커 해석 플랫폼 that preserves the laboratory’s own reference interval and flags unit mismatches when comparing historical reports. This is especially useful when testing crosses borders or laboratories; a true trend requires the same assay, same specimen, and similar health conditions.

If MPO is unexpectedly elevated, repeat it after at least 2 to 4 weeks without acute illness and after avoiding unusually strenuous exercise for 24 to 48 hours, unless your clinician has a reason to test sooner. Do not repeat indefinitely: two well-timed values usually answer whether the first result was transient.

Lower category on one EDTA-plasma assay <350 pmol/L Lower observed MPO category; does not exclude atherosclerosis or acute coronary syndrome.
Intermediate category 350-539 pmol/L Interpret with illness, smoking, renal function, lipids, blood pressure, and assay details.
Higher category ≥540 pmol/L May indicate greater inflammatory oxidative activity; not diagnostic of coronary disease.
No universal critical MPO value Assay-specific Urgency is driven by symptoms, ECG, troponin, and clinical assessment, not MPO alone.

A Sensible Follow-Up Plan for Elevated MPO

An elevated MPO result should trigger a structured cardiovascular review, not panic and not automatic medication. The first steps are confirming assay context, excluding recent inflammatory triggers, and measuring established modifiable risks.

Clinician reviews longitudinal MPO, lipid and blood pressure results without identifying patient details
그림 13: A useful MPO follow-up compares trends with established cardiovascular risk markers.

Start with symptoms and urgency. Chest pressure, exertional breathlessness, syncope, new neurologic symptoms, or a markedly unwell state need real-time medical assessment; asymptomatic patients can usually arrange a non-urgent appointment to review risk over the next few weeks.

Then check the fundamentals: blood pressure averages, fasting or non-fasting lipid panel, non-HDL-C, ApoB when indicated, HbA1c or glucose, eGFR, urine ACR, smoking/vaping exposure, sleep, medications, and family history. A 혈액 검사 타임라인 helps identify whether illness, diet, or a medication change distorted the draw.

Kantesti AI can compare dates and help prepare questions for a clinician, while our 임상 워크플로우 예시 show why results should be reviewed as patterns rather than isolated flags. It does not replace an ECG, imaging decision, physical examination, or individual prescribing advice.

Coronary artery calcium scanning can be useful for selected asymptomatic adults when a treatment decision remains uncertain after conventional assessment. It is not appropriate for everyone, and a high MPO alone is not a standard indication; age, calculated risk, radiation considerations, and the likely management consequence matter.

Can Lifestyle Changes Lower MPO and Cardiac Risk?

Lifestyle measures may reduce inflammatory burden and cardiovascular risk, but no guideline recommends treating a laboratory MPO target. The reliable goal is lowering causal risk factors: ApoB-containing lipoproteins, blood pressure, tobacco exposure, diabetes risk, inactivity, and poor sleep.

Mediterranean-style meal preparation and brisk walking equipment beside vascular lab monitoring tools
그림 14: Lifestyle changes target established vascular risks rather than chasing an MPO number.

A Mediterranean-style dietary pattern, regular aerobic and resistance activity, adequate sleep, weight management when appropriate, and tobacco cessation improve risk factors with established outcome evidence. For triglycerides, reducing refined carbohydrates and alcohol exposure can matter substantially; see practical options for lowering triglycerides before retesting.

Antioxidant supplements have not earned a role as MPO-lowering cardiovascular therapy. High-dose vitamin E, beta-carotene, and mixed products can have harms or drug interactions, and a decline in a surrogate marker is not proof of fewer heart attacks or strokes.

The evidence for directly lowering MPO is not mature enough to prescribe around. If LDL-C falls from 170 to 85 mg/dL on a clinician-agreed plan, blood pressure falls from 148/92 to 126/78 mmHg, and smoking stops, I consider that a strong preventive success even if MPO has not been repeated.

Use trends sensibly: comparable lipid and blood-pressure trends are clinically stronger than frequent inflammatory-marker testing. Our 종단적(시간에 따른) 검사실 분석 가이드 explains what to record before deciding that a biomarker has genuinely changed.

The Bottom Line: Put MPO in a Full Cardiovascular Assessment

MPO is a biologically meaningful oxidative-stress marker, but it cannot diagnose blocked arteries, exclude a heart attack, or replace established cardiovascular prevention tools. Its greatest limitation is nonspecificity: the same elevation can reflect vascular inflammation, infection, smoking, kidney disease, or another immune trigger.

A useful MPO discussion includes LDL-C or non-HDL-C, ApoB where relevant, Lp(a) at least once, blood-pressure averages, HbA1c or glucose, kidney function, urine albumin, smoking status, family history, symptoms, and medication history. A normal MPO does not cancel high ApoB or hypertension, and an elevated MPO does not prove plaque is present.

Dr. Thomas Klein’s practical rule is straightforward: test results should change a safe next action. If MPO does not alter prevention treatment, imaging, symptom triage, or the timing of a repeat assessment, it may be interesting but not clinically decisive.

Kantesti combines multilingual report interpretation with trend review, and its medical content is overseen through our 의료 자문 위원회. For methodology and limitations, review our technical clinical validation approach 자동 해석에 의존하기 전에.

Take urgent symptoms seriously regardless of MPO. For stable prevention, bring the full panel and your home blood-pressure readings to a qualified clinician; that conversation is where a specialized marker earns its place—or is appropriately set aside.

자주 묻는 질문

높은 미엘로퍼옥시다아제 검사 결과는 무엇을 의미하나요?

높은 골수과산화효소(myeloperoxidase) 수치는 MPO 방출 면역세포의 순환 활동 증가를 의미하며, 이는 산화 스트레스 및 혈관 염증을 동반할 수 있습니다. 흔히 사용되는 EDTA-플라즈마 분석법에서 540 pmol/L 이상의 수치는 높은 범주에 속하지만, 검사실별 특정 범위가 항상 우선합니다. 감염, 흡연, 신장 질환, 자가면역 활동, 잇몸 염증, 최근의 격렬한 운동도 MPO 수치를 높일 수 있습니다. 높은 수치는 관상동맥 질환을 진단하거나 심장마비가 발생하고 있음을 증명하지는 않습니다.

MPO 혈액 검사 정상 결과는 무엇인가요?

MPO 혈액 검사 결과에 대한 보편적으로 단일한 정상 수치는 없는데, 검사 시약에서 다른 검체, 보정 물질, 단위를 사용하기 때문이다. 흔히 인용되는 EDTA 플라즈마 검사의 경우, 350 pmol/L 미만을 낮은 범주, 350~539 pmol/L를 중간 범주, 540 pmol/L 이상을 높은 범주로 본다. 이러한 수치는 ng/mL로 보고된 MPO 결과나 검사실 자체의 참고 범위가 없는 혈청 검사에는 적용해서는 안 된다. 정상 MPO 수치라고 해서 높은 LDL-C, 높은 ApoB, 관상동맥 플라크 또는 급성 관상동맥 증후군을 배제할 수는 없다.

MPO는 심장병을 진단할 수 있나요?

아니요, MPO는 관상동맥 협착, 플라크 부담, 심근 손상 또는 흉통의 원인을 보여주지 않기 때문에 심장 질환을 진단할 수 없습니다. 관상동맥 질환의 진단은 증상, 검진, ECG, 급성 질환 가능 시 고감도 트로포닌, 위험 평가, 그리고 때로는 관상동맥 영상 또는 부하 검사에 의존합니다. 급성 흉통의 경우, 대략 1~3시간 동안의 연속적인 트로포닌 측정은 MPO보다 훨씬 더 임상적으로 유용합니다. MPO는 특정 상황에서 2차 위험 정보를 추가할 수 있지만, 단독으로 사용되는 진단 검사는 아닙니다.

MPO와 MPO-ANCA는 같은 것인가요?

아니요, MPO 효소 검사와 MPO-ANCA 검사는 다른 질문에 답합니다. MPO 심장 검사는 순환하는 myeloperoxidase 농도 또는 활성을 측정하며, 종종 pmol/L 단위로, MPO-ANCA 검사는 MPO에 대한 항체를 측정하며, 종종 U/mL 또는 분석 지수 단위로 보고됩니다. MPO-ANCA는 증상, 소변 검사, 신장 기능, 영상 검사 및 전문가 평가와 함께 소혈관 혈관염 가능성 평가에 사용됩니다. 높은 심혈관 MPO 결과가 반드시 혈관염이 있다는 것을 의미하지는 않습니다.

MPO 수치가 높을 때 어떤 검사를 받아야 하나요?

An elevated MPO should be interpreted with blood pressure, LDL-C, non-HDL-C, ApoB when indicated, lipoprotein(a), HbA1c or glucose, eGFR, urine albumin-creatinine ratio, smoking exposure, symptoms, and family history. ApoB of 130 mg/dL or higher and Lp(a) of 50 mg/dL or 125 nmol/L or higher are recognized risk-enhancing findings in common prevention frameworks. If chest pain, severe breathlessness, fainting, or neurologic symptoms are present, ECG and urgent high-sensitivity troponin testing take priority. Repeat MPO only when well and preferably after 2 to 4 weeks using the same laboratory and specimen type.

How can I lower my myeloperoxidase level?

There is no proven treatment target for lowering myeloperoxidase itself, so clinicians focus on changes that reduce cardiovascular events. These include stopping tobacco, controlling blood pressure, lowering LDL-C and ApoB when indicated, improving glucose control, exercising regularly, and following a sustainable dietary pattern. Avoid starting antioxidant supplements solely to change an MPO number because marker changes do not prove fewer heart attacks or strokes. A repeat result is most meaningful when measured with the same assay after recovery from illness and avoidance of unusually strenuous exercise for 24 to 48 hours.

오늘 AI 기반 혈액검사 분석 받기

즉시 정확한 검사 분석을 위해 Kantesti를 신뢰하는 전 세계 200만 명 이상의 사용자와 함께하세요. 혈액검사 결과를 업로드하고 몇 초 만에 15,000+ 바이오마커에 대한 포괄적인 해석을 받아보세요.

📚 참고된 연구 출판물

1

Klein, T., Mitchell, S., & Weber, H. (2026). Kantesti LTD. (2026). Iron Studies Guide: TIBC, Iron Saturation & Binding Capacity. Zenodo. https://doi.org/10.5281/zenodo.18248745 | ResearchGate: https://www.researchgate.net/ | Academia.edu: https://www.academia.edu/. Kantesti AI 의학 연구.

2

Klein, T., Mitchell, S., & Weber, H. (2026). Kantesti LTD. (2026). aPTT Normal Range: D-Dimer, Protein C Blood Clotting Guide. Zenodo. https://doi.org/10.5281/zenodo.18262555 | ResearchGate: https://www.researchgate.net/ | Academia.edu: https://www.academia.edu/. Kantesti AI 의학 연구.

📖 외부 의학 참고문헌

3

Brennan ML et al. (2003). Prognostic value of myeloperoxidase in patients with chest pain. 뉴잉글랜드 의학저널(NEJM).

4

Meuwese MC et al. (2007). Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. 미국심장학회지(Journal of the American College of Cardiology).

5

Arnett DK 등 (2019). 심혈관질환의 1차 예방에 관한 2019 ACC/AHA 가이드라인. Circulation.

200만+분석된 테스트
127+국가
75+언어

⚕️ 의료 면책 조항

E-E-A-T 신뢰 신호

경험

의사가 주도하는 검사 해석 워크플로 임상 검토.

📋

전문적 지식

임상 맥락에서 바이오마커가 어떻게 거동하는지에 대한 검사실 의학 중심.

👤

권위

Dr. Thomas Klein이 작성했으며 Dr. Sarah Mitchell과 Prof. Dr. Hans Weber가 검토했습니다.

🛡️

신뢰성

경고를 줄이기 위한 명확한 후속 경로가 포함된 근거 기반 해석.

🏢 칸테스티 LTD 잉글랜드 & 웨일스에 등록 · 회사 번호. 17090423 런던, 영국 · 칸테스티.넷
blank
Prof. Dr. Thomas Klein에 의해

Thomas Klein 박사는 Kantesti AI의 최고 의료 책임자(CMO)로 재직 중인 보드 인증 임상 혈액종양내과 전문의입니다. 실험실 의학 분야에서 15년 이상의 경험을 보유하고 있으며, 혈액검사 결과의 AI 지원 해석에 큰 관심을 가지고 있습니다. 그는 새로운 기술을 일상적인 임상 진료와 연결하기 위해 노력합니다. 그의 관심 분야에는 생체표지자 분석, 임상 의사결정 지원 연구, 인구집단별 기준 범위 최적화가 포함됩니다. CMO로서 그는 플랫폼의 내부 벤치마킹에 대한 임상적 의견을 제공하고, Kantesti의 교육 보고서에 대한 의학적 품질에 대해 임상적 감독을 제공합니다.

답글 남기기

이메일 주소는 공개되지 않습니다. 필수 필드는 *로 표시됩니다